CAR-T cell manufacturing: Major process parameters and next-generation strategies
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoim...
Uložené v:
| Vydané v: | The Journal of experimental medicine Ročník 221; číslo 2 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
05.02.2024
|
| Predmet: | |
| ISSN: | 1540-9538, 1540-9538 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies. |
|---|---|
| AbstractList | Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies. Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies. |
| Author | Khericha, Mobina Ayala Ceja, Melanie Chen, Yvonne Y Harris, Caitlin M Puig-Saus, Cristina |
| Author_xml | – sequence: 1 givenname: Melanie orcidid: 0000-0002-2906-5786 surname: Ayala Ceja fullname: Ayala Ceja, Melanie organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA – sequence: 2 givenname: Mobina orcidid: 0000-0002-6734-7741 surname: Khericha fullname: Khericha, Mobina organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA – sequence: 3 givenname: Caitlin M orcidid: 0000-0003-2325-1729 surname: Harris fullname: Harris, Caitlin M organization: Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA, USA – sequence: 4 givenname: Cristina orcidid: 0000-0002-3014-3649 surname: Puig-Saus fullname: Puig-Saus, Cristina organization: Parker Institute for Cancer Immunotherapy Center at University of California-Los Angeles , Los Angeles, CA, USA – sequence: 5 givenname: Yvonne Y orcidid: 0000-0002-5583-119X surname: Chen fullname: Chen, Yvonne Y organization: Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38226974$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtLAzEYxINU7ENvniVHL1vz3sRbKb6gIko9L9nsl7Klm61JFvS_t2IFT_M7DMPMTNEo9AEQuqRkTokWN1vo5owwTgzhJ2hCpSCFkVyP_vEYTVPaEkKFkOoMjblmTJlSTNDrcvFWrLGD3Q53NgzeujzENmxu8bPd9hHvY-8gJby30XaQISZsQ4MDfOZiAwGizW0fcMoHgE0L6RydertLcHHUGXq_v1svH4vVy8PTcrEqHNcyF8o7TTSpDQjGlaek4Z7WUGtf06akhjunGC0VlUawWlFCtKfSsrLk2hoKbIauf3MPDT8GSLnq2vSzwwboh1QxQ6VURhJ5sF4drUPdQVPtY9vZ-FX93cC-AdkdX8k |
| CitedBy_id | crossref_primary_10_3389_fmed_2025_1591287 crossref_primary_10_3390_ijms26125524 crossref_primary_10_1016_j_isci_2025_112553 crossref_primary_10_3390_cancers16162913 crossref_primary_10_1002_btm2_10753 crossref_primary_10_3390_cimb47050321 crossref_primary_10_1007_s00761_025_01779_0 crossref_primary_10_3389_fimmu_2025_1557157 crossref_primary_10_1016_j_omtm_2025_101526 crossref_primary_10_1186_s40164_024_00522_6 crossref_primary_10_1038_s41416_025_03100_7 crossref_primary_10_1016_j_ymthe_2024_11_017 crossref_primary_10_1186_s40364_025_00807_w crossref_primary_10_1038_s41409_025_02637_8 crossref_primary_10_1002_ctm2_70306 crossref_primary_10_1002_jha2_1047 crossref_primary_10_1186_s12943_025_02386_8 crossref_primary_10_3389_fimmu_2024_1502712 crossref_primary_10_61186_ibj_4444 crossref_primary_10_1007_s13671_025_00472_0 crossref_primary_10_1002_btpr_70045 crossref_primary_10_1080_1750743X_2025_2461987 crossref_primary_10_1111_imcb_12799 crossref_primary_10_1093_neuonc_noae203 crossref_primary_10_1111_trf_18167 crossref_primary_10_1016_j_ymthe_2025_07_045 crossref_primary_10_1002_bit_70005 crossref_primary_10_1016_S2352_3026_24_00273_4 crossref_primary_10_1208_s12248_025_01017_w crossref_primary_10_3389_fimmu_2025_1635159 crossref_primary_10_1038_s41598_025_14865_5 crossref_primary_10_1182_blood_2024026758 crossref_primary_10_3390_cells14151147 crossref_primary_10_3390_cancers16162858 crossref_primary_10_1053_j_seminhematol_2024_09_001 crossref_primary_10_1007_s12015_024_10786_4 crossref_primary_10_1002_wnan_2017 crossref_primary_10_3390_ijms26136320 crossref_primary_10_3389_fimmu_2024_1453740 crossref_primary_10_1016_j_molimm_2025_05_019 crossref_primary_10_1093_ndt_gfae160 crossref_primary_10_1016_j_jtct_2024_07_011 crossref_primary_10_1088_1361_6528_add482 crossref_primary_10_1016_j_jconrel_2025_02_057 crossref_primary_10_1007_s12015_025_10904_w crossref_primary_10_3389_fbioe_2024_1452674 crossref_primary_10_1016_j_lpm_2024_104265 crossref_primary_10_35754_0234_5730_2025_70_2_208_228 crossref_primary_10_1016_j_jconrel_2025_114072 crossref_primary_10_1016_j_transci_2025_104251 crossref_primary_10_1093_noajnl_vdaf028 crossref_primary_10_1080_21645515_2025_2558403 crossref_primary_10_1016_j_bcp_2024_116439 crossref_primary_10_1186_s13045_025_01737_8 crossref_primary_10_1007_s12672_025_03360_y crossref_primary_10_1038_s41409_025_02582_6 crossref_primary_10_1007_s00281_024_01019_4 crossref_primary_10_1016_j_tips_2025_08_004 crossref_primary_10_1016_j_ymthe_2025_08_032 crossref_primary_10_1186_s12964_024_01995_y crossref_primary_10_1007_s13402_025_01056_7 crossref_primary_10_1016_j_retram_2024_103491 crossref_primary_10_7759_cureus_65291 crossref_primary_10_1016_j_critrevonc_2025_104647 crossref_primary_10_1038_s41409_024_02504_y crossref_primary_10_1038_s41392_025_02269_w crossref_primary_10_1016_j_critrevonc_2025_104648 crossref_primary_10_1016_j_omton_2025_200980 crossref_primary_10_3389_fimmu_2025_1520063 crossref_primary_10_1016_j_omtm_2025_101566 crossref_primary_10_1007_s12032_025_02984_y crossref_primary_10_1007_s12032_025_02735_z crossref_primary_10_3389_fmed_2024_1527600 crossref_primary_10_3390_biomedicines13092314 crossref_primary_10_1136_jitc_2025_011690 crossref_primary_10_1016_j_intimp_2025_115321 crossref_primary_10_1186_s13148_025_01856_6 crossref_primary_10_1016_j_amjmed_2025_03_024 crossref_primary_10_1016_j_tips_2024_03_004 crossref_primary_10_1002_advs_202412225 crossref_primary_10_1007_s00262_025_04106_z crossref_primary_10_3389_fimmu_2025_1513148 crossref_primary_10_1007_s12519_025_00876_9 crossref_primary_10_35754_0234_5730_2025_70_2_252_263 crossref_primary_10_1007_s43152_025_00064_x crossref_primary_10_3389_fimmu_2024_1411393 crossref_primary_10_3389_fimmu_2025_1665488 crossref_primary_10_1126_scitranslmed_ado2084 crossref_primary_10_3390_cancers16122270 crossref_primary_10_3390_cancers16223867 crossref_primary_10_3389_fimmu_2025_1597888 crossref_primary_10_1002_adtp_202500094 crossref_primary_10_1007_s13312_024_3300_3 crossref_primary_10_3390_cells14030203 crossref_primary_10_1016_j_ccell_2025_03_019 crossref_primary_10_3389_fimmu_2025_1564998 crossref_primary_10_1016_j_exphem_2025_104762 crossref_primary_10_1016_j_jcyt_2025_05_006 crossref_primary_10_3390_ijms25179518 crossref_primary_10_1007_s10555_024_10214_6 |
| ContentType | Journal Article |
| Copyright | 2024 Ayala Ceja et al. |
| Copyright_xml | – notice: 2024 Ayala Ceja et al. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1084/jem.20230903 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1540-9538 |
| ExternalDocumentID | 38226974 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA211015 – fundername: California Institute for Regenerative Medicine grantid: TRAN1-11555 – fundername: Parker Institute for Cancer Immunotherapy – fundername: Jean and Stephen Kaplan |
| GroupedDBID | --- -~X 18M 29K 2WC 36B 4.4 53G 5GY 5RE 5VS ABOCM ABZEH ACGFO ACNCT ACPRK ADBBV AENEX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C45 CGR CS3 CUY CVF D-I DIK DU5 E3Z EBS ECM EIF EMB F5P F9R GX1 H13 HYE IH2 KQ8 L7B N9A NPM O5R O5S OK1 P2P P6G R.V RHI SJN TR2 TRP UHB W8F WOQ 7X8 |
| ID | FETCH-LOGICAL-c385t-6fc8080b9e4236f10d3f1beb8fb1d7193cc6217615942b61008f15a27738a91e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 121 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001143331800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1540-9538 |
| IngestDate | Thu Oct 02 11:02:34 EDT 2025 Wed Jul 23 01:46:32 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2024 Ayala Ceja et al. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c385t-6fc8080b9e4236f10d3f1beb8fb1d7193cc6217615942b61008f15a27738a91e2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-3014-3649 0000-0002-6734-7741 0000-0003-2325-1729 0000-0002-2906-5786 0000-0002-5583-119X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10791545 |
| PMID | 38226974 |
| PQID | 2915569505 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2915569505 pubmed_primary_38226974 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-05 |
| PublicationDateYYYYMMDD | 2024-02-05 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of experimental medicine |
| PublicationTitleAlternate | J Exp Med |
| PublicationYear | 2024 |
| SSID | ssj0014456 |
| Score | 2.6876616 |
| SecondaryResourceType | review_article |
| Snippet | Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| SubjectTerms | Autoimmune Diseases Humans Immunotherapy, Adoptive T-Lymphocytes |
| Title | CAR-T cell manufacturing: Major process parameters and next-generation strategies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38226974 https://www.proquest.com/docview/2915569505 |
| Volume | 221 |
| WOSCitedRecordID | wos001143331800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3Ivga1jZp2vgiMhw-uDFlwt5Kmos4WDvXzd9vTtqxJ0HwpU8pJCcnyXdu30HoTpsgMVRrwnXCCKNMEulAHJE65UqZWErj2fVfksEgHY_FsHG4VU1a5epO9Be1LhX4yDsREJlz4R7sh9kXga5REF1tWmhsohZ1UAa0OhmvowiM-e6tIQT_hTvZTeJ7kLLOxEAZusPfwrfL-gVc-kemt__f6R2gvQZe4sdaHw7RhimO0E6_CaAfo9fu4xsZYXDX46ksllDX4AsV73FfTso5ntWFAxgowaeQKlNhWWhcgIH84SmqYSdxtVhRTJyg997TqPtMmq4KRNE0XhBuFXBJ5sI4JMVtGGhqw9zkqc1DnTg8pxR3dopDOoJFOQfyHxvGMkoSmkoRmugUbRVlYc4RjrmOWB5bN54zsBQlo5KqgNlIcBmZNrpdCStzWgtrk4Upl1W2FlcbndUSz2Y1vUZGHWbhzsy5-MPfl2jX7SLzadTxFWpZd2bNNdpW34vPan7j1cF9B8P-D8Duvxc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CAR-T+cell+manufacturing%3A+Major+process+parameters+and+next-generation+strategies&rft.jtitle=The+Journal+of+experimental+medicine&rft.au=Ayala+Ceja%2C+Melanie&rft.au=Khericha%2C+Mobina&rft.au=Harris%2C+Caitlin+M&rft.au=Puig-Saus%2C+Cristina&rft.date=2024-02-05&rft.issn=1540-9538&rft.eissn=1540-9538&rft.volume=221&rft.issue=2&rft_id=info:doi/10.1084%2Fjem.20230903&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1540-9538&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1540-9538&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1540-9538&client=summon |